Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

New

E7820

An angiogenesis inhibitor
Catalog #: B2600
SKU-Size Size Price Qty
B2600-5 5 mg
$75.00
B2600-25 25 mg
$275.00
More Sizes Get Quote

Product Details

Alternate Name 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-benzenesulfonamide
Peptide Sequence N/A
Appearance Beige solid
CAS # 289483-69-8
Molecular Formula C₁₇H₁₂N₄O₂S
Molecular Weight 336.37
Purity ≥98% by HPLC
Solubility >30 mg/ml in DMSO
SMILES CC1=C2C(=CNC2=C(C=C1)NS(=O)(=O)C3=CC=CC(=C3)C#N)C#N
InChi InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
InChi Key LWGUASZLXHYWIV-UHFFFAOYSA-N
PubChem CID 196970
Handling Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Storage Conditions -20ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

E7820 is a small molecule sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.